GHK-Cu route changes the question
Route means how something reaches the body: on the skin, for example, or by injection. That detail matters when a skin-cream finding gets used to support an injection claim.
GHK is a short chain of three amino acids, the building blocks used in proteins. GHK-Cu is GHK bound to copper. We keep both the form and the route in view.
A cream has to get through skin
The skin’s outer layer is a barrier. A review of topical GHK research describes how hard it is for the peptide to cross it. Topical simply means applied to the skin.
So “contains GHK-Cu” isn’t enough to describe what was tested. How a cream is made can affect delivery. Activity in a dish doesn’t tell us what that cream will achieve on someone’s skin. The ingredient still has a journey to make.
Copper was measured, not whole-body rejuvenation
In an experiment using removed human skin, copper applied as GHK-Cu passed through skin layers. Some stayed in a deeper layer. The researchers measured copper.
That doesn’t show that the intact GHK-Cu complex travels the same way through a living person. It also doesn’t answer an injection question. It’s a delivery finding under specific test conditions, with no whole-body benefit established by that experiment.
A mixture can’t tell us what one ingredient did
A hair-growth trial tested GHK mixed with another ingredient, 5-aminolevulinic acid. Hair counts increased compared with placebo, a preparation without the active mixture. We can’t tell how much each ingredient contributed. This was not a trial of pure GHK-Cu.
Skin irritation is possible with topical copper peptides. Injection safety is much less established. Whether long-term use inside the body could disturb copper balance is a theoretical concern, not a demonstrated poisoning outcome here.
Two words to keep apart
ingredient
An ingredient is one part of a preparation. GHK, GHK-Cu and the hair-study mixture aren’t interchangeable. Sharing a few letters doesn’t give them the same results. The exact preparation matters as much as the familiar name.
treatment
For injectable GHK-Cu, FDA’s list as of April 22, 2026 records a nomination that has been withdrawn. That doesn’t clear it for a pharmacy to make it to order. The entry is specific to injections; it doesn’t describe every form of GHK-Cu.
A doctor or pharmacist can check an Australian product and its intended use. A cream’s familiarity cannot establish an injection’s benefits or safety. The comparison page has more on keeping the tested product attached to its result.